The transaction, which is expected to close in few months, is subject to certain closing conditions and does not involve Catalent’s Clinical Supply Services operations in Philadelphia, or the Blow-Fill-Seal business in Woodstock.
The transaction does not involve any commercial packaging activity that Catalent conducts outside North America.
Catalent’s decision to sell US commercial packaging operations is because of its strategy to focus on growing its businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic and other products.